30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Exactech Posts 3Q16 Revenue -

Exactech (EXAC) reported 3Q16 revenue of US $59.9MM, +6.5% from 3Q15. All growth is as reported. 

ORTHOWORLD estimates 3Q16 segment sales and growth on an as-reported basis, as follows.

  • Joint Reconstruction $55.5MM, +9.8% (Includes Other revenue attributed to subsegments)
    • Hips $12.4MM, +12.7%
    • Knees $18.6MM, +6.3%
    • Extremities Recon $24.6MM, +11.1%
  • Spine $1.9MM, -18.9%
  • Orthobiologics $2.5MM, -24.9%


  • Hips supported by Alteon Monoblock Revision; added ~10 more sets in 3Q; will be fully launched in 1H17
  • Moving from pilot to limited launch in revision knee; expecting more substantial set availability in mid- to late-2Q17
  • Momentum in Extremities Recon born of continued adoption of Equinoxe shoulder, competitive glenoid offerings, with contribution from humeral reconstruction prosthesis
  • Completed first surgeries with ExactechGPS total shoulder application; expanded to revision total knee application in the U.S.
  • Successfully treated first patient with Vantage Total Ankle; pilot phase commenced in 4Q
  • All joint segments successfully developing U.S. sales channels
  • Spine and biologics results attributed to price pressures, slower product adoption

2017 product pipeline includes:

  • Alteon HA-coated hip stem (next-gen of former Element hip stem)
  • Modular version of Alteon Monoblock revision stem
  • Significant investments to come in total knees
  • New short humeral stem for Equinoxe shoulder
  • GPS for revision knee
  • Line extension to Pro spinal products
  • Acapella anchored cervical interbody V2


Sources: Exactech, Inc.; ORTHOWORLD Inc.



This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.